海曲泊帕与环孢素在中国健康受试者中的药物相互作用I期研究
结果显示多剂量环孢素对海曲泊帕暴露无临床显著影响,单剂量海曲泊帕对环孢素稳态暴露也无影响,两药合用总体耐受良好。
要点
- 环孢素多剂量对海曲泊帕暴露无临床显著影响。
- 单剂量海曲泊帕对环孢素稳态暴露无影响。
- 海曲泊帕与环孢素合用总体耐受良好。
核心结论
- 海曲泊帕与环孢素合用未观察到有临床意义的药物相互作用。
主要发现
- 海曲泊帕与环孢素合用对比海曲泊帕单用的Cmax几何均值比为95.97%(90%CI 70.08-131.43%)。
- 海曲泊帕与环孢素合用对比海曲泊帕单用的AUC0-t几何均值比为105.75%(90%CI 75.04-149.04%)。
- 海曲泊帕与环孢素合用对比海曲泊帕单用的AUCinf几何均值比为104.19%(90%CI 74.71-145.32%)。
- 环孢素与海曲泊帕合用对比环孢素单用的稳态Cmax几何均值比为100.49%(90%CI 91.89-109.89%)。
- 环孢素与海曲泊帕合用对比环孢素单用的稳态AUC几何均值比为100.81%(90%CI 107.88-103.82%)。
临床怎么用
- 基于该研究结果,海曲泊帕与环孢素合用无需进行剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aims to evaluate the drug-drug interaction (DDI) between hetrombopag and cyclosporine in healthy Chinese subjects. METHODS: Twenty-six eligible subjects enrolled in this single-centre, single-sequence, open-label, DDI study with 3 treatment periods, receiving 5 mg hetrombopag once on Day 1, 100 mg cyclosporine twice daily from Day 11 to Day 15 and 5 mg hetrombopag + 100 mg cyclosporine on Day 16. Serial blood samples were collected for pharmacokinetic evaluation. Adverse events were monitored throughout the study. RESULTS: The plasma hetrombopag geometric mean ratios (90% confidence interval) of maximum plasma concentration, area under the plasma concentration-time curve (AUC) from predose to time of last quantifiable sample and AUC to infinity of coadministration of hetrombopag with cyclosporine vs. hetrombopag alone were 95.97% (70.08-131.43%), 105.75% (75.04-149.04%) and 104.19% (74.71-145.32%), respectively, indicating multiple doses of cyclosporine had minimal effects on hetrombopag exposure. The geometric mean ratios (90% confidence interval) of maximum blood concentration and AUC at steady state during a dosing interval for blood cyclosporine of coadministration vs. cyclosporine alone were 100.49% (91.89-109.89%) and 100.81% (107.88-103.82%), respectively, suggesting a single dose of hetrombopag had no impact on the exposure of cyclosporine. Coadministration of hetrombopag with cyclosporine was generally well tolerated. CONCLUSION: No clinically significant DDI was observed when coadministration of hetrombopag with cyclosporine. The results of this study will inform the appropriate use of this combination therapy both in clinical trials and clinical settings.
引用
- Li F, Lin H, Feng S, et al. A phase I, single-sequence, open-label study to evaluate the drug-drug interaction between hetrombopag and cyclosporine in healthy Chinese subjects. Br J Clin Pharmacol. 2023. PMID: 36654488. doi:10.1111/bcp.15664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。